The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series

The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series

Ofatumumab (OFA) is an anti-CD20 antibody. We assessed the therapeutic potential of OFA in five pediatric anti-NMDAR encephalitis patients who showed poor responses to the first-line immunotherapy. OFA treatment showed clinical improvement including alleviation of clinical symptoms and mRS decrease...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wenlin Wu, Jie Hong, Yanping Ran, Wenxiao Wu, Haixia Zhu, Chi Hou, Yuanyuan Gao, Yulin Tang, Yinting Liao, Wen-Xiong Chen, Xiaojing Li
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Heliyon
Subjects:	Refractory Anti-NMDAR encephalitis Children Ofatumumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844024167114
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review
by: Min Deng, et al.
Published: (2025-03-01)

Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report
by: Xin Tu, et al.
Published: (2025-08-01)

Case Report: Anti-NMDAR encephalitis associated with neurobrucellosis: causality or coexistence?
by: Yao Wang, et al.
Published: (2025-05-01)

Autoimmune encephalitis: case reports of anti-NMDAR and anti-CASPR2 encephalitides and literature review
by: J. Kazlauskaitė, et al.
Published: (2021-12-01)

Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis
by: Min Deng, et al.
Published: (2024-11-01)

Frequency, characteristics, and immunological accompaniments of ataxia in anti-NMDAR antibody-associated encephalitis
by: Sarah Jesse, et al.
Published: (2024-12-01)

Psychiatric conditions with a known pathogenesis: anti-NMDAr encephalitis in the field of pediatric and adolescent psychiatry
by: Aleksandr V. Abramov, et al.
Published: (2024-04-01)

Comparative efficacy of intravenous immunoglobulin and protein A immunoadsorption in severe anti-NMDAR encephalitis
by: Xuhui Tang, et al.
Published: (2025-08-01)

CSF Mitochondrial N-Formyl Methionine Peptide as Complementary Diagnostic Tool in Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
by: Li C, et al.
Published: (2024-12-01)

Clinical features of autonomic dysfunction in children with anti-N-methyl-D aspartic receptor encephalitis
by: Dongqing Li, et al.
Published: (2025-01-01)

Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series
by: Chen Min, et al.
Published: (2025-01-01)

Case Report: Clinical features and management of anti-mGluR1 encephalitis: case illustration and review of the literature
by: Min Deng, et al.
Published: (2025-07-01)

Ofatumumab for the management of refractory pemphigus vulgaris: A case series
by: Sera Sarsam, MBBS, BMedSc, et al.
Published: (2025-10-01)

The spectrum of overlapping anti-NMDAR encephalitis and demyelinating syndromes: a systematic review of presentation, diagnosis, management, and outcomes
by: Saboor Saeed, et al.
Published: (2025-12-01)

Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review
by: Jingliang Zhang, et al.
Published: (2025-02-01)

Electroencephalographic biomarkers of antibody-mediated autoimmune encephalitis
by: Lu Sun, et al.
Published: (2025-03-01)

Neurochemical and molecular characteristics of altered brain functional activity in the anti-NMDAR encephalitis
by: Xiarong Gong, et al.
Published: (2025-10-01)

Ovarian teratoma with anti-N-methyl-D-aspartate receptor encephalitis, a type of limbic encephalitis: a review of the literature and a case report in Korea
by: S.H. Park, et al.
Published: (2020-10-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01)

Post-Herpetic Anti-NMDAR Encephalitis in Denmark: Current Status and Future Challenges
by: Anna Søgaard, et al.
Published: (2024-08-01)

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
by: Maxime Teisseyre, et al.
Published: (2025-03-01)

Reconstitution of CXCR3+ CCR6+ Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis
by: Shu Yang, et al.
Published: (2025-05-01)

Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis
by: Amy Perrin Ross, et al.
Published: (2025-01-01)

Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis
by: Wioletta Katarzyna Żukowicz-Wyrwa, et al.
Published: (2025-08-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Case report: Overlapping syndrome of MOG-IgG associated optic neuritis and autoimmune encephalitis with co-existence of anti-NMDAR and anti-GABABR antibodies
by: Zhujun Mei, et al.
Published: (2025-01-01)

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura
by: Yuki Yokota, et al.
Published: (2025-03-01)

Diagnostic pitfalls in a young Romanian ranger with an acute psychotic episode
by: Nagy E, et al.
Published: (2016-05-01)

The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database
by: Xiwen Zhang, et al.
Published: (2025-07-01)

Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy
by: Jie Chen, et al.
Published: (2025-06-01)

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01)

Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy
by: Awada Z, et al.
Published: (2024-12-01)

Explosive‐Onset Epilepsia Partialis Continua and Chorea
by: Peter F. Sarnacki, et al.
Published: (2025-03-01)

GLS1‐Mediated Redundancy in Glutamate Accelerates Arterial Calcification via Activating NMDAR/Ca2+/β‐Catenin Pathway
by: Ziting Zhou, et al.
Published: (2025-06-01)

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
by: Tjalf Ziemssen, et al.
Published: (2024-12-01)

Impact of electro-acupuncture on EAAT2 and NMDAR-2B expression in goats with visceral hypersensitivity
by: Adnan Hassan Tahir, et al.
Published: (2024-12-01)

Non-Hodgkin’s Lymphoma of the Central Nervous System with N-Methyl-D-Aspartate Receptor Antibody Positivity - A Case Report
by: Handenur Tunc, et al.
Published: (2024-04-01)

COVID-19 Vaccination Response in Patients with Multiple Sclerosis Treated with Ofatumumab in the United States: A Medical Record Review
by: Rahul H. Dave, et al.
Published: (2024-10-01)

Immune inflammatory regulation in Anti-NMDAR encephalitis: insights from transcriptome analysis
by: Shan Qiao, et al.
Published: (2025-05-01)